November 29, 2016 - By Adrian Mccoy
Trading of Pfizer (NYSE:PFE)‘s shares is going to be interesting today. Barclays increased the stock from a “Equal-Weight” to a “Overweight”.
Out of 18 analysts covering Pfizer (NYSE:PFE), 7 rate it a “Buy”, 0 “Sell”, while 11 “Hold”. This means 39% are positive. $51 is the highest target while $34 is the lowest. The $39.29 average target is 23.32% above today’s ($31.86) stock price. Pfizer has been the topic of 38 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The stock of Pfizer Inc. (NYSE:PFE) has “Buy” rating given on Tuesday, June 14 by Jefferies. On Tuesday, September 13 the stock rating was maintained by Jefferies with “Buy”. The firm has “Overweight” rating given on Friday, August 28 by Piper Jaffray. On Wednesday, November 2 the stock rating was downgraded by BMO Capital Markets to “Market Perform”. The firm earned “Market Perform” rating on Monday, May 2 by Leerink Swann. Credit Suisse maintained Pfizer Inc. (NYSE:PFE) rating on Monday, May 9. Credit Suisse has “Outperform” rating and $39 price target. As per Friday, August 14, the company rating was maintained by Piper Jaffray. Jefferies maintained the shares of PFE in a report on Thursday, July 14 with “Buy” rating. The stock of Pfizer Inc. (NYSE:PFE) earned “Overweight” rating by Piper Jaffray on Friday, August 28. The firm earned “Hold” rating on Wednesday, April 6 by Societe Generale.
About 10.99M shares traded hands. Pfizer Inc. (NYSE:PFE) has declined 4.57% since April 26, 2016 and is downtrending. It has underperformed by 9.83% the S&P500.
Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on February, 7. They expect $0.50 EPS, down 5.66% or $0.03 from last year’s $0.53 per share. PFE’s profit will be $3.02 billion for 15.93 P/E if the $0.50 EPS becomes a reality. After $0.61 actual EPS reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -18.03% negative EPS growth.
Insitutional Activity: The institutional sentiment increased to 1.18 in 2016 Q2. Its up 0.15, from 1.03 in 2016Q1. The ratio is positive, as 80 funds sold all Pfizer Inc. shares owned while 704 reduced positions. 127 funds bought stakes while 678 increased positions. They now own 4.15 billion shares or 5.76% less from 4.40 billion shares in 2016Q1.
New England Professional Planning Grp Inc Inc, a Rhode Island-based fund reported 236,821 shares. Northstar Asset Mngmt Llc last reported 32,800 shares in the company. Department Mb Fincl Bank N A accumulated 12,054 shares or 0.05% of the stock. Alexandria Cap Ltd Liability Corporation accumulated 0.02% or 3,491 shares. Fred Alger Mngmt Inc has 0.02% invested in the company for 110,867 shares. Bridges Investment reported 28,220 shares or 0.16% of all its holdings. Inr Advisory Svcs Llc holds 0.23% or 35,341 shares in its portfolio. Fayez Sarofim & Company owns 668,809 shares or 0.13% of their US portfolio. Van Hulzen Asset Mgmt Limited Liability Company, a California-based fund reported 30,929 shares. Solaris Asset accumulated 0.51% or 19,975 shares. Blue Fincl Inc, a Rhode Island-based fund reported 42,622 shares. Jaffetilchin Invest Partners Ltd Co holds 0.09% of its portfolio in Pfizer Inc. (NYSE:PFE) for 8,869 shares. Cwm Limited Liability Com accumulated 0.84% or 325,478 shares. Martingale Asset Management Limited Partnership last reported 0.59% of its portfolio in the stock. S&Co Inc has invested 0.14% of its portfolio in Pfizer Inc. (NYSE:PFE).
Insider Transactions: Since November 4, 2016, the stock had 0 insider buys, and 2 selling transactions for $882,530 net activity. $552,530 worth of Pfizer Inc. (NYSE:PFE) shares were sold by BOURLA ALBERT. Shares for $330,000 were sold by MADDALUNA ANTHONY J on Wednesday, November 9.
Pfizer Inc. is a research-based global biopharmaceutical company. The company has a market cap of $192.42 billion. The Firm is engaged in discovering, developing and manufacturing of healthcare products. It has a 31.81 P/E ratio. The Company’s divisions include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
According to Zacks Investment Research, “Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Pfizer’s Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. is headquartered in New York.”
Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research global biopharmaceutical company. The Firm is engaged in discovering, developing and manufacturing of healthcare products. The Company’s divisions include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The Company’s portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. The Company’s biopharmaceutical products include Lipitor, Sutent and the Premarin family of products. The Company’s biotechnology products include BeneFIX, ReFacto and Xyntha.
More important recent Pfizer Inc. (NYSE:PFE) news were published by: Bloomberg.com which released: “Pfizer Ends Cholesterol Drug Trials as Earnings Fall Short” on November 01, 2016, also Fool.com published article titled: “Better Buy: Gilead Sciences Inc. vs. Pfizer Inc.”, Schaeffersresearch.com published: “Analyst Upgrades: Pfizer Inc., JPMorgan Chase & Co., and Goldman Sachs Group Inc” on November 29, 2016. More interesting news about Pfizer Inc. (NYSE:PFE) was released by: Fool.com and their article: “Is Pfizer Inc.’s 6.4% Drop in October the Beginning of a Long Downtrend?” with publication date: November 07, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy